These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 16343860)

  • 1. Diminished neurocardiac dynamics associated with antipsychotic-induced extrapyramidal syndrome.
    Kim JH; Yi SH; Park KT; Ahn YM; Lee KY; Yang SA; Kim YS
    Eur Neuropsychopharmacol; 2006 Aug; 16(6):459-63. PubMed ID: 16343860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart rate dynamics and their relationship to psychotic symptom severity in clozapine-treated schizophrenic subjects.
    Kim JH; Yi SH; Yoo CS; Yang SA; Yoon SC; Lee KY; Ahn YM; Kang UG; Kim YS
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):371-8. PubMed ID: 14751435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia.
    Cortese L; Caligiuri MP; Williams R; Schieldrop P; Manchanda R; Malla A; Harricharan R
    J Clin Psychopharmacol; 2008 Feb; 28(1):69-73. PubMed ID: 18204344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic treatment and extrapyramidal symptoms amongst schizophrenic inpatients.
    Høiberg MP; Nielsen B
    Nord J Psychiatry; 2006; 60(3):207-12. PubMed ID: 16720511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating subjective domains of antipsychotic-induced adverse effects using heart rate variability.
    Chang JS; Hwang SS; Yi SH; Kim Y; Lee YS; Kim YS; Jung HY
    Psychiatry Clin Neurosci; 2015 May; 69(5):283-91. PubMed ID: 25066617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motor and mental aspects of extrapyramidal syndromes.
    Casey DE
    Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():105-14. PubMed ID: 8866772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurological complications of psychiatric drugs: clinical features and management.
    Haddad PM; Dursun SM
    Hum Psychopharmacol; 2008 Jan; 23 Suppl 1():15-26. PubMed ID: 18098217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
    Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
    Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
    Nasrallah HA; Brecher M; Paulsson B
    Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinematic analysis of handwriting movements in schizophrenic patients.
    Gallucci RM; Phillips JG; Bradshaw JL; Vaddadi KS; Pantelis C
    Biol Psychiatry; 1997 Apr; 41(7):830-3. PubMed ID: 9084903
    [No Abstract]   [Full Text] [Related]  

  • 12. Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder.
    Gentile S
    J Clin Psychopharmacol; 2007 Feb; 27(1):35-45. PubMed ID: 17224710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
    Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular risks of atypical antipsychotic drug treatment.
    Drici MD; Priori S
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):882-90. PubMed ID: 17563919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-motor cognitive-perceptual dysfunction associated with drug-induced parkinsonism.
    Kim JH; Byun HJ
    Hum Psychopharmacol; 2009 Mar; 24(2):129-33. PubMed ID: 19204914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative measurement of handwriting in the assessment of drug-induced parkinsonism.
    Caligiuri MP; Teulings HL; Filoteo JV; Song D; Lohr JB
    Hum Mov Sci; 2006 Oct; 25(4-5):510-22. PubMed ID: 16647772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between neuroleptic extrapyramidal syndromes and patients' all-cause mortality.
    Modestin J; Vogt Wehrli M; Stephan PL; Agarwalla P
    Pharmacopsychiatry; 2009 Mar; 42(2):57-60. PubMed ID: 19308879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Extrapyramidal side-effects: avoidance, diagnosis and treatment].
    Fleischhacker WW; Widschwendter C
    Psychiatr Prax; 2005 Apr; 32 Suppl 1():S25-30. PubMed ID: 15818517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.
    Crescenti A; Mas S; Gassó P; Parellada E; Bernardo M; Lafuente A
    Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):807-11. PubMed ID: 18346175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.